hexylresorcinol has been researched along with Carcinoma, Squamous Cell in 3 studies
Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, SG | 3 |
| Choi, JY | 3 |
| Jeong, JH | 2 |
| Park, YW | 1 |
| Song, JY | 1 |
| Kim, AS | 2 |
| Chae, WS | 1 |
| Kweon, H | 1 |
3 other studies available for hexylresorcinol and Carcinoma, Squamous Cell
| Article | Year |
|---|---|
4-hexylresorcinol exerts antitumor effects via suppression of calcium oscillation and its antitumor effects are inhibited by calcium channel blockers.
Topics: Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Calcium Channel Blockers; Calcium Signaling; | 2013 |
4-Hexylresorcinol inhibits transglutaminase-2 activity and has synergistic effects along with cisplatin in KB cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Pro | 2011 |
4-hexylresorcinol stimulates the differentiation of SCC-9 cells through the suppression of E2F2, E2F3 and Sp3 expression and the promotion of Sp1 expression.
Topics: Carcinoma, Squamous Cell; Cell Differentiation; Cell Growth Processes; Cell Line, Tumor; E2F2 Transc | 2012 |